BCR-ABL Kinase Inhibitors
Customize your policy alerts
Sign up for Premera Bluecross Policy 5.01.518 alerts
Get alerted when Policy 5.01.518 changes without checking for updates manually.
Monitor payer policy activity
This policy governs pharmacy-benefit coverage and prior authorization for selected BCR-ABL tyrosine kinase inhibitors used to treat Philadelphia chromosome-positive leukemias and other specified malignancies or hematologic disorders. Coverage is determined by drug-specific medical-necessity criteria, including diagnosis, age, prior therapy response or intolerance, combination therapy, quantity limits, and continued clinical response.
The policy revised criteria for imatinib, dasatinib, and nilotinib and added indications for bosutinib and ponatinib.
The policy recognizes NCCN Category 1 and 2A indications as proven and Category 2B and 3 indications as unproven.
The policy clarified first-line and second-line therapy roles for BCR-ABL inhibitors.
The initial authorization period for other reviews changed from 3 months to 6 months.
Brand nilotinib tartrate was assigned a limit of 120 tablets per 30 days.
Coverage criteria were added for generic bosutinib.
Bosulif coverage now requires a trial of generic bosutinib.
Coverage criteria were added for Cavhanza (nilotinib) for adults with Philadelphia chromosome-positive chronic myeloid leukemia.
References to non-formulary exception reviews were removed.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.